Spironolactone for heart failure with preserved ejection fraction Academic Article uri icon

Overview

MeSH Major

  • Heart Failure
  • Mineralocorticoid Receptor Antagonists
  • Spironolactone

abstract

  • In patients with heart failure and a preserved ejection fraction, treatment with spironolactone did not significantly reduce the incidence of the primary composite outcome of death from cardiovascular causes, aborted cardiac arrest, or hospitalization for the management of heart failure. (Funded by the National Heart, Lung, and Blood Institute; TOPCAT ClinicalTrials.gov number, NCT00094302.).

publication date

  • January 2014

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1056/NEJMoa1313731

PubMed ID

  • 24716680

Additional Document Info

start page

  • 1383

end page

  • 92

volume

  • 370

number

  • 15